NFKB1 and myeloid sarcoma: Previous studies, also reviewed by Zhou et al. 2020 [6], have shown that some of the approved clinical treatments for MS, such as dimethyl fumarate, FTY720 (fingolimod) and laquinimod have therapeutic effects by partially blocking the inflammatory cascade of the NF-κB pathway of the peripheral immune system or the CNS immune response mediated by astrocytes [6, 50].